NIDDK

Insulin in vials
May 20, 2021

Beta cell regeneration

Vanderbilt researchers dissected the complex microenvironment of the pancreatic islet to discover the signals that drive beta cell regeneration — as a possible treatment for diabetes.

By Leigh MacMillan
April 15, 2021

New insights into kidney development

Integrin-linked kinase, a central component of a complex that coordinates cell signaling involved in migration, proliferation and cell death, plays a role in kidney development and epithelial cell function.

By Bill Snyder
From left, Kimryn Rathmell, MD, PhD, Bradley Reinfeld, Matthew Madden and Jeffrey Rathmell, PhD, have discovered that immune cells — not cancer cells — are the major glucose consumers in the tumor microenvironment, upending a century-old observation.
April 7, 2021

Study revises understanding of cancer metabolism

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

By Leigh MacMillan
March 18, 2021

HIV, diabetes and immune cells in fat

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

By Leigh MacMillan
March 11, 2021

Electronic health record study discovers novel hormone deficiency

A novel hormone deficiency may exist in humans, Vanderbilt investigators have discovered. In an analysis of two decades worth of electronic health records, the researchers found that some patients have unexpectedly low levels of natriuretic peptide hormone in clinical situations that should cause high levels of the hormone.

By Leigh MacMillan
March 4, 2021

Probiotic protection

A probiotic factor given early in life to mice prevented intestinal inflammation in adulthood, providing a rationale for probiotic intervention in individuals at high risk of developing inflammatory bowel disease.

By Anivarya Kumar
March 4, 2021

Targeting glucagon action in diabetes

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.
By Leigh MacMillan
February 18, 2021

Gene variant and glucose metabolism

Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study.
By Leigh MacMillan
February 4, 2021

Potential biomarker for IBD severity, cancer risk identified

A selenium transport protein produced in the colon may be a novel biomarker for assessing disease severity and cancer risk in patients with inflammatory bowel disease.
By Leigh MacMillan
February 4, 2021

Gene network for leukemia factor

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.
By Leigh MacMillan
January 28, 2021

Diabetes Day focuses on diversity, inclusion in research

Vanderbilt Diabetes Day, an annual event which showcases the work of outstanding scholars and researchers in the fields of diabetes and endocrinology from throughout the United States, looked quite a bit different in November 2020 as the attendees connected virtually for sessions presented over two days.
By Jill Clendening
November 17, 2020

A cohort for type 2 diabetes studies

A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs.
By Leigh MacMillan
November 3, 2020

New treatment for a rare obesity

Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.
By Bill Snyder
1 … 3 4 5 6 7 … 24